Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2009

View Archived Issues

Mechanisms of Destiny Pharma antibacterial candidates compared against S. aureus

Angion Biomedica discovers novel PARP inhibitors for the treatment of stroke

Nerve growth factor peptidomimetic MIM-D3 improves experimental dry eye

Besifloxacin shows high antibacterial activity against bacterial conjunctivitis in clinical trials

GSK offers Q1 report

Further in vitro and in vivo data on novel macrolide CEM-101 available

Novel T-type calcium channel blockers patented by Merck & Co. as antiepileptic agents

Daiichi Sankyo claims novel antidiabetic compounds

Sanofi-aventis discovers novel vanilloid TRPV1 receptor antagonists for the treatment of pain

Janssen claims novel PARP-1 inhibitors for cancer treatment

Akela and Nventa close merger agreement

Watson launches Gelnique for women with overactive bladder

Emisphere receives payment from MannKind following FDA acceptance of Afresa NDA

CSTP in Japan awards grants to NIBIO to study flu vaccine using Hemispherx's Ampligen

PharmAthene submits regulatory strategy to FDA for rPA anthrax vaccine SparVax

Bioniche presents update on phase III clinical program for Urocidin in bladder cancer

Roche reports positive 2-year data from LITHE study of Actemra in rheumatoid arthritis

Sanofi Pasteur receives order from HHS to initiate production of a A(H1N1) vaccine

Replikins reports results from analysis of peptide genomic sequence data for H1N1 virus

GSK receives order from HHS for A(H1N1) influenza vaccine antigen and adjuvant

Phase II study finds Nefecon reduces urine albumin in IgA nephropathy patients / News in Context

Type II calcimimetic compound ASP-7991 shows preclinical potential as antihyperparathyroidism drug

CAT-354, an anti-IL-13 human monoclonal antibody for asthma therapy deemed safe in healthy subjects

Scancell receives grant from U.K. EMDA to fund SCIB-1 DNA vaccine

Astellas launches Protopic in Europe in a new twice-weekly regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...